BEIJING, Sept. 8, 2026 /PRNewswire/ -- On September 8, Waterdrop Inc. (NYSE: WDH) released its unaudited financial results for the second quarter ended June 30, 2026. In Q2 2026, the company's operating revenue reached RMB1,448.2 million, up 72.8% year-over-year; net profit attributable to ordinary shareholders was RMB125.8 million, marking 18 consecutive quarters of profitability. As of August 31, 2026, the company had cumulatively repurchased approximately 62.9 million ADSs (American Depositary Shares) from the open market.

With solid performance in Q2, the company achieved rapid revenue growth. Going forward, Waterdrop will continue to increase investment in AI technology innovation, making healthcare and financial services more accessible to the public.

Insurance Business Grows Steadily, AI Penetration Continues to Rise

This quarter, the insurance business maintained strong growth, with insurance-related revenue up 80.5% year-over-year. Meanwhile, profitability continued to improve, with insurance business operating profit reaching RMB183.6 million, up 20% quarter-over-quarter. Waterdrop is comprehensively accelerating the application of AI technology across the entire insurance value chain. Premiums facilitated by 'AI Medical Insurance Expert' rose by 25.6% quarter-over-quarter. First-year premiums for long-term insurance grew 33.4% quarter-over-quarter.

In terms of product innovation, leveraging its massive claims data and user profile analytics, Waterdrop has broken the traditional static logic of blanket rejection for people with chronic diseases, removing barriers to coverage for users with pre-existing conditions one by one. This quarter, Waterdrop launched 'Rongyibao,' the market's first long-term critical illness insurance product that requires no health disclosure and offers five-year guaranteed renewability, covering more than 100 critical illnesses with optional riders for accidental death and disability benefits. At the same time, the company expanded 'Jixing Gaozhao' series with the market's first lifetime specified disease insurance product requiring no health disclosure.

Waterdrop Medical Crowdfunding: 499 Million Users Have Donated RMB74.7 Billion to 3.82 Million Patients

This quarter, Waterdrop Medical Crowdfunding continued to fulfill its role in providing emergency relief. Since its launch in 2016, approximately 499 million donors have cumulatively contributed RMB74.7 billion to 3.82 million patients with critical illnesses through Waterdrop Medical Crowdfunding.

Waterdrop Medical Crowdfunding has always practiced the philosophy of "tech for good," building a dual safeguard system for case authenticity verification and transparent fund flow through AI technology. This quarter, Waterdrop Medical Crowdfunding introduced AI in risk management: relying on the semantic parsing capabilities of large models combined with strategic analysis, it built an intelligent identification matrix for multiple high-risk scenarios, precisely detecting dimensions such as fundraiser sensitive-identity recognition and abnormal assets. This has significantly improved the accuracy and efficiency of platform risk identification, ensuring the authenticity and reliability of fundraising cases.

In addition, Waterdrop Medical Crowdfunding has launched AI fundraising assistants in 548 cities nationwide. Leveraging intelligent, round-the-clock service, the assistants provide professional support to fundraising users across the country — especially those in remote areas and those unfamiliar with internet operations. Services cover end-to-end fundraising Q&A, basic critical-illness health education, and efficient fundraising guidance, making critical illness relief more precise and convenient and filling gaps left by human service coverage.

E-Find Platform: Q2 Revenue RMB35.2 Million, Partners with 255 Pharma Companies and CROs

Waterdrop's digital clinical trial solutions business grew steadily, with E-Find Platform's net revenue reaching RMB35.2 million, up 26.8% year-over-year. This quarter, E-Find Platform established partnerships with 255 well-known domestic and overseas pharma companies and CROs. As of June 30, 2026, it had cumulatively delivered 1,873 clinical trial projects with 17,052 enrolled patients.

In terms of social responsibility, in response to severe rainstorms and floods across multiple areas of Guangxi and debris-flow disasters at the Jilong Port in Jilong County, Shigatse, Tibet, Waterdrop urgently established a disaster relief emergency response team and quickly launched rescue operations. Waterdrop Charity immediately launched a "Relief" special section on its homepage and, in collaboration with multiple foundations, rushed aid to affected areas — delivering over 2,000 relief supply packages to the Guangxi disaster zone and doing its utmost to help affected communities through the crisis.

Shen Peng, Founder and CEO of Waterdrop Inc., said: "Waterdrop has always regarded technology as our core driver. With AI embedded across our platforms, we are well positioned to capture the growing demand in our existing businesses. In the future, we remain committed to delivering greater value for our shareholders in the years to come."